Eli Lilly stops experimental Cancer Drug Enzastaurin Development

Lymphoma drug, Enzastaurin, fails In late-stage trial

Eli Lilly stops Development of Experimental #Cancer Drug #Enzastaurin
Eli Lilly made $27.7 Billion in Profits between 2003-2012 – sources HuffPolitics Blog

Eli Lilly said it will stop development of Enzastaurin experimental cancer drug after it failed in a late-stage trial to delay a worsening of symptoms in patients with lymphoma, but continues with late-stage trials of two other experimental cancer drugs.

Read Eli Lilly Lymphoma Drug, Enzastaurin, Fails In Late-Stage Trial HuffPost Healthy Living, 05/10/2013

All our posts tagged Eli Lilly – Big PharmaDrugs